Abstract: The present invention relates to the use of mono- and bis nitrosylated propanediols, and compositions and formulations comprising the same, in methods for the treatment of a microbial infection.

Abstract: The present invention relates to methods of treating a condition wherein NO has a beneficial effect, wherein such treatment comprises administering certain mono- and/or bis nitrosylated propanediols, including compositions and formulations thereof, wherein administration of said compounds, compositions or formulations is indirect to the pulmonary circulation and/or the systemic circulation of a patient in need thereof.

Abstract: Disclosed is a process for the synthesis of mono- and bis-nitrosylated propanediols, as well as compositions and pharmaceutical formulations that includes the compounds. The process proceeds by reacting a corresponding propanediol that is not nitrosylated with a source of nitrite, optionally in the presence of a suitable acid. When the source of nitrite is an organic nitrite, reacting step is performed in a suitable organic solvent, and when the source of nitrite is an inorganic nitrite, the reacting step is performed in a bi-phasic solvent mixture comprising an aqueous phase and a non-aqueous phase. Also disclosed are methods of treating a condition wherein administration of nitric oxide (NO) has a beneficial effect by administering said compounds, compositions or formulations.

Abstract: A hearing prosthesis circuit includes a power source, a first amplifier coupled to the power source, and a second amplifier coupled to the power source. The circuit also includes a stimulation component coupled to the first amplifier and the second amplifier. The stimulation component is configured to provide an output in accordance with an electrical signal that includes audio data. Further, the circuit includes a controller coupled to the first amplifier and the second amplifier. The controller is operable in accordance with a first operational setting to use the first amplifier to provide the electrical signal to the stimulation component and the controller is also operable in accordance with a second operational setting to use the second amplifier to provide the electrical signal to the stimulation component. Generally, the first amplifier provides greater signal amplification of the audio data than the second amplifier.

Abstract: A hearing prosthesis circuit includes a power source, a first amplifier coupled to the power source, and a second amplifier coupled to the power source. The circuit also includes a stimulation component coupled to the first amplifier and the second amplifier. The stimulation component is configured to provide an output in accordance with an electrical signal that includes audio data. Further, the circuit includes a controller coupled to the first amplifier and the second amplifier. The controller is operable in accordance with a first operational setting to use the first amplifier to provide the electrical signal to the stimulation component and the controller is also operable in accordance with a second operational setting to use the second amplifier to provide the electrical signal to the stimulation component. Generally, the first amplifier provides greater signal amplification of the audio data than the second amplifier.

Abstract: A hearing prosthesis circuit includes a power source, a first amplifier coupled to the power source, and a second amplifier coupled to the power source. The circuit also includes a stimulation component coupled to the first amplifier and the second amplifier. The stimulation component is configured to provide an output in accordance with an electrical signal that includes audio data. Further, the circuit includes a controller coupled to the first amplifier and the second amplifier. The controller is operable in accordance with a first operational setting to use the first amplifier to provide the electrical signal to the stimulation component and the controller is also operable in accordance with a second operational setting to use the second amplifier to provide the electrical signal to the stimulation component. Generally, the first amplifier provides greater signal amplification of the audio data than the second amplifier.

Abstract: A hearing prosthesis circuit includes a power source, a first amplifier coupled to the power source, and a second amplifier coupled to the power source. The circuit also includes a stimulation component coupled to the first amplifier and the second amplifier. The stimulation component is configured to provide an output in accordance with an electrical signal that includes audio data. Further, the circuit includes a controller coupled to the first amplifier and the second amplifier. The controller is operable in accordance with a first operational setting to use the first amplifier to provide the electrical signal to the stimulation component and the controller is also operable in accordance with a second operational setting to use the second amplifier to provide the electrical signal to the stimulation component. Generally, the first amplifier provides greater signal amplification of the audio data than the second amplifier.

Abstract: A hearing prosthesis circuit includes a power source, a first amplifier coupled to the power source, and a second amplifier coupled to the power source. The circuit also includes a stimulation component coupled to the first amplifier and the second amplifier. The stimulation component is configured to provide an output in accordance with an electrical signal that includes audio data. Further, the circuit includes a controller coupled to the first amplifier and the second amplifier. The controller is operable in accordance with a first operational setting to use the first amplifier to provide the electrical signal to the stimulation component and the controller is also operable in accordance with a second operational setting to use the second amplifier to provide the electrical signal to the stimulation component. Generally, the first amplifier provides greater signal amplification of the audio data than the second amplifier.

Abstract: This invention relates to novel pharmaceutically useful compounds of formula (I), in particular compounds that are competitive inhibitors of trypsin-like serine proteases, especially thrombin, their use as medicaments, pharmaceutical compositions containing them and synthetic routes to their production.

Abstract: This invention relates to novel pharmaceutically useful compounds of formula (I), in particular compounds that are competitive inhibitors of trypsin-like serine proteases, especially thrombin, their use as medicaments, pharmaceutical compositions containing them and synthetic routes to their production.

Abstract: This invention relates to novel pharmaceutically useful compounds of formula (I), in particular compounds that are competitive inhibitors of trypsin-like serine proteases, especially thrombin, their use as medicaments, pharmaceutical compositions containing them and synthetic routes to their production.

Abstract: This invention relates to novel pharmaceutically useful compounds of formula (I), in particular compounds that are competitive inhibitors of trypsin-like serine proteases, especially thrombin, their use as medicaments, pharmaceutical compositions containing them and synthetic routes to their production.

Abstract: There is provided a compound of formula I wherein R1 to R5, A, G, L and X have meanings given in the description, which compounds are useful as, or are useful as prodrugs of, competitive inhibitors of trypsin-like proteases, such as thrombin, and thus, in particular, in the treatment of conditions where inhibition of thrombin is beneficial (e.g. conditions, such as thrombo-embolisms, where inhibition of thrombin is required or desired, and/or conditions where anticoagulant therapy is indicated).

Abstract: The invention relates to heterocyclic derivatives of formula (I), wherein R2 is amino, a group OR4 or a group —Y—R5 where R4 is hydrogen or C1-4alkyl, Y is C1-4alkylene, R5 is hydrogen, halo, hydroxy, C1-2alkoxy, C1-2alkoxyC1-2alkoxyC1-4, or a group NR7R8 where R7 and R8 are independently selected from hydrogen, C1-2alkyl, hydroxyC1-2alkyl or alkoxyC1-2alkyl, or R7 and R8 together with the nitrogen atom to which they are attached form a saturated 5-6-membered heterocyclic ring which optionally contains an additional heteroatom; n is one or two and each R1 is independently selected from halo, haloC1-2alkyl, hydroxy, oxo, amino, C1-2alkylamino or di-C1-2dialkylamino; or a pharmaceutically acceptable salt thereof. These compounds possess antithrombotic and anticoagulant properties and are accordingly useful in methods of treatment of humans or animals.

Abstract: There is provided a compound of formula (I) wherein R1, R2a, R2b, R3a, R3b, R4, R5a, R5b, R6 to R8, A and G have meanings given in the description, which compounds are useful as, or are useful as prodrugs of, competitive inhibitors of trypsin-like proteases, such as thrombin, and thus, in particular, in the treatment of conditions where inhibition of thrombin is beneficial (e.g. conditions, such as thrombo-embolisms, where inhibition of thrombin is required or desired, and/or conditions where anticoagulant therapy is indicated).

Abstract: There is provided a compound of formula I wherein the dashed line, R1, R2, R3a, R3b, A, D, E, G and L have meanings given in the description, which compounds are useful as, or are useful as prodrugs of, competitive inhibitors of trypsin-like proteases, such as thrombin, and thus, in particular, in the treatment of conditions where inhibition of thrombin is beneficial (e.g. conditions, such as thrombo-embolisms, where inhibition of thrombin is required or desired, and/or conditions where anticoagulant therapy is indicated).

Abstract: The invention relates to heterocyclic derivatives of formula (I), wherein R2 is amino, a group OR4 or a group —Y—R5 where R4 is hydrogen or C1-4alkyl, Y is C1-4alkylene, R5 is hydrogen, halo, hydroxy, C1-2alkoxy, C1-2alkoxyC1-2alkoxyC1-4, or a group NR7R8 where R7 and R8 are independently selected from hydrogen, C1-2alkyl, hydroxyC1-2alkyl or alkoxyC1-2alkyl, or R7 and R8 together with the nitrogen atom to which they are attached form a saturated 5-6-membered heterocyclic ring which optionally contains an additional heteroatom; n is one or two and each R1 is independently selected from halo, haloC1-2alkyl, hydroxy, oxo, amino C1-2alkylamino or di-C1-2dialkylamino; or a pharmaceutically acceptable salt thereof. These compounds possess antithrombotic and anticoagulant properties and are accordingly useful in methods of treatment of humans or animals.

Abstract: There is provided a compound of formula (I) wherein R1, R2a, R2b, R3a, R3b, R4, R5, R6, A, G and L have meanings given in the description, which compounds are useful as, or are useful as prodrugs of, competitive inhibitors of trypsin-like proteases, such as trombin, and thus, in particular, in the treatment of conditions where inhibition of thrombin is beneficial (e.g. conditions, such as thrombo-embolisms, where inhibition of trombin is required or desired, and/or conditions whereas anticoagulant therapy is indicated).

Abstract: Method and device for suspending a cab (4) on a vehicle frame (3) using vertical orientation for both a first element (1) that absorbs shocks/vibrations from the vehicle frame (3) to the cab (4) and a second element (2) that acts as a load support between cab (4) and the vehicle frame (3)in the event of, for example, accident situations. The first and second elements (1, 2) are arranged on the device, which connects the cab (4) to the vehicle frame (3) by a firm connection between the first element (1) and the cab (4), or alternatively the vehicle frame (3).

Abstract: Pharmaceutical preparation containing an effective amount of acetylsalicylic acid and a compound of Formula I. A1—A2—NH—(CH2)n—B wherein A1, A2, n and B are as defined in the specification, which is either the compound as such, or a stereoisomer thereof, and which may be in the form of a physiologically acceptable salt, in association with a pharmaceutical carrier. The combinations are suitable for use in inhibiting thrombin, or in the treatment or prophylaxis of thrombosis or hypercoagulability in patients in need thereof.